Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

sanofi-aventis imparts new cannabinoid CB2 receptor antagonists for pain relief

Feb. 20, 2009

New gamma-secretase inhibitors reported in recent Schering-Plough patent

Feb. 20, 2009

AVI BioPharma treats first patient in AVI-4658 Duchenne muscular dystrophy trial

Feb. 20, 2009

TRPV1-mediated analgesic activity is enhanced by repeated administration of ABT-102

Feb. 20, 2009

FDA extends Hemispherx's NDA review date for Ampligen in CFS

Feb. 19, 2009

FDA sets PDUFA date for review of Zogenix's NDA for migraine drug Sumavel DosePro

Feb. 19, 2009

Phase III SOFIA study does not achieve primary endpoint in autistic disorder

Feb. 19, 2009

Pharmos agrees to sell PRS-639058 and other CB2 agonists to Reperio

Feb. 19, 2009

Cipher receives tentative FDA approval for extended-release tramadol

Feb. 18, 2009

Depomed initiates phase I DM-1992 trial in Parkinson's disease

Feb. 18, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...